Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction

Corvus Pharmaceuticals, Inc.

2025-Q2 EPS reported -$0.26 vs consensus -$0.14 ▼ miss (-82.3%)

Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).
Cash, equivalents, securities $74.4M as of June 30, 2025; warrant exercise proceeds $35.7M in Q2.
Soquelitinib Phase 1 atopic dermatitis: cohort 3 mean EASI reduction 64.8% at day 28 vs 54.6% for cohorts 1-2 and 34.4% placebo.
50% of evaluable cohort 3 patients had ≥4 point itch reduction (PP-NRS) at day 28; Phase 2 on track by year-end.
Phase 3 PTCL registrational trial enrolling; cash expected to fund operations into Q4 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.